Jonathan P Graham - Net Worth and Insider Trading
Jonathan P Graham Net Worth
The estimated net worth of Jonathan P Graham is at least $19 Million dollars as of 2023-09-23. Jonathan P Graham is the EVP, Gen. Counsel & Secy. of Amgen Inc and owns about 37,333 shares of Amgen Inc (AMGN) stock worth over $10 Million. Jonathan P Graham is also the Senior VP & GC of Danaher Corp and owns about 34,606 shares of Danaher Corp (DHR) stock worth over $9 Million. Details can be seen in Jonathan P Graham's Latest Holdings Summary section.
Transaction Summary of Jonathan P Graham
Jonathan P Graham Insider Ownership Reports
Jonathan P Graham Latest Holdings Summary
Jonathan P Graham currently owns a total of 2 stocks. Among these stocks, Jonathan P Graham owns 37,333 shares of Amgen Inc (AMGN) as of May 10, 2022, with a value of $10 Million and a weighting of 53.76%. Jonathan P Graham also owns 34,606 shares of Danaher Corp (DHR) as of May 19, 2015, with a value of $9 Million and a weighting of 46.24%.
Jonathan P Graham Form 4 Trading Tracker
According to the SEC Form 4 filings, Jonathan P Graham has made a total of 3 transactions in Amgen Inc (AMGN) over the past 5 years, including 0 buys and 3 sells. The most-recent trade in Amgen Inc is the sale of 13,500 shares on May 10, 2022, which brought Jonathan P Graham around $3 Million.
According to the SEC Form 4 filings, Jonathan P Graham has made a total of 0 transactions in Danaher Corp (DHR) over the past 5 years. The most-recent trade in Danaher Corp is the sale of 30,232 shares on May 19, 2015, which brought Jonathan P Graham around $3 Million.
Insider Trading History of Jonathan P Graham
Jonathan P Graham Trading Performance
Jonathan P Graham Ownership Network
Ownership Network List of Jonathan P Graham
Ownership Network Relation of Jonathan P Graham
Jonathan P Graham Owned Company Details
What does Amgen Inc do?
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amjevita (biosimilar Humira).
Who are the key executives at Amgen Inc?
Jonathan P Graham is the SVP & Gen. Counsel & Secy. of Amgen Inc. Other key executives at Amgen Inc include VP & Finance & CAO Matthew C. Busch , SVP & Human Resources Derek Miller , and SVP & Business Development Rachna Khosla .
Amgen Inc (AMGN) Insider Trades Summary
Over the past 18 months, Jonathan P Graham made 1 insider transaction in Amgen Inc (AMGN) with a net sale of 13,500. Other recent insider transactions involving Amgen Inc (AMGN) include a net sale of 800 shares made by R Sanders Williams , a net sale of 9,558 shares made by Murdo Gordon , and a net sale of 6,600 shares made by Robert Eckert .
In summary, during the past 3 months, insiders sold 9,558 shares of Amgen Inc (AMGN) in total and bought 0 shares, with a net sale of 9,558 shares. During the past 18 months, 31,390 shares of Amgen Inc (AMGN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 31,390 shares.
Amgen Inc (AMGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Amgen Inc Insider Transactions
Jonathan P Graham Mailing Address
Above is the net worth, insider trading, and ownership report for Jonathan P Graham. You might contact Jonathan P Graham via mailing address: 2099 Pennsylvania Avenue, Nw, 12th Floor, Washington Dc 20006.